• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
China Anti-tumor Drugs Market Report, 2007 Product Image

China Anti-tumor Drugs Market Report, 2007

  • Published: June 2007
  • 16 pages
  • Research In China

The anti-tumor drugs market operated well in 2006, and the total sales volume amounted to USD 34.6 billion, up 20.5% from a year earlier, and the growth margin ranked the first place among all the treatment categories to be the most important drive force for promoting the global drugs market. According to the increase trend in recent five years, it is forecasted that the anti-tumor drugs will probably be the unit product with the largest sales income in the global drugs market.

According to the forecast of IXIS, the molecule-targeted drugs will stand out singly, its annual compound growth rate (ACGR) will reach 23% in 2005-2010, and the market share will be from 39% in 2005 to 53.6% in 2010.

The total sales of anti-tumor drugs (except traditional Chinese medicine) in China amounted to RMB 6.002 billion in 2006, up 23.94% year-on-year. It is forecasted that the total sales of anti-tumor drugs (except traditional Chinese medicine) in China will reach RMB 7.6 billion in 2007, rising above 25% from a year earlier.

1 Status Quo and Development Trend of Global Anti-tumor Drugs Market
1.1 Classified Anti-tumor drugs become the rapidest increase field in global drugs market
1.2 Molecule-targeted drugs of anti-tumor increases fast
1.3 R&D of anti-tumor drugs field is still active

2 Chinese Anti-tumor Drugs Market
2.1 Chinese anti-tumor drugs Market
2.2 Chinese enterprises

3 Major Companies
3.1 Hengrui
3.2 Hansoh
3.3 Hisun
3.4 Wanle

Drugs Industry Development Trend
R/E Ratio Change of Roche, 2001-2007
Tumor Patient Occurrence Rate in China
Sales Change of Anti-tumor drugs (except Traditional Chinese Medicine) in China
Forecast of Hengrui Sales Income
Main Anti-tumor Drugs Increase of Hengrui
Docetaxel Sales Income and Increase of Hengrui
Oxaliplatin Sales Income and Increase of Hengrui
Irinotecan Hydrochloride Infusion Sales Income and Increase of Hengrui
Sales Income of Hansoh
Main Anti-tumor Drugs of Hansoh
Sales Income of Hisun
Main Anti-tumor Drugs of Hisun
Sales Income of Wanle
Current Equity Structure of Wanle
Top Ten Classified Drugs in Global Drugs Market by Sales, 2006
Forecast of Top Three Anti-tumor Drugs Increase
Forecast of Anti-tumor Drugs Market Shares of Key Companies
Top Global 500 Anti-tumor Drugs by Sales, 2005
Main Classifications of Anti-tumor Drugs in China
Chinese Enterprises with Sales Income of Anti-tumor Drugs above RMB 100 Million
Foreign Enterprises with Sales Income of Anti-tumor Drugs above RMB 100 Million
Market Shares Change Trend of China Anti-tumor Drugs (excluding Traditional Chinese Medicine)

Hengrui, Hansoh, Hism and Wanle

Format Properties
Hard Copy A printed copy of the report will be shipped to you.
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format.
Enterprisewide The report will be emailed to you. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos